Picture of PLx Pharma Winddown logo

PLXPQ — PLx Pharma Winddown News Story

0.000.00%
us flag iconLast trade - 00:00
FinancialsHighly SpeculativeMicro CapValue Trap

PLx Pharma Inc expected to post a loss of 56  cents a share - Earnings Preview

* PLx Pharma Inc  PLXP.OQ   PLXP.O  is expected to show a
rise in
quarterly revenue when it reports  results on August 12. 
    * The Sparta New Jersey-based  company is expected to report
revenue of $3.533 million, according to the mean estimate from 3
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for PLx Pharma Inc is
for a
loss of 56 cents per share. For the same quarter last year, the
company reported a loss of 79 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for PLx Pharma
Inc is
$11​, above​ its last closing price of $1.96. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.73       -0.72      -0.39     Beat    46.1
 Dec. 31 2022  -0.71       -0.71      0.10      Beat    114
 Sep. 30 2021  -0.47       -0.46      -0.80     Missed  -72.4​
 Jun. 30 2021  -0.23       -0.22      -0.79     Missed  -264.6
 ​​Mar.        -0.21       -0.21      -0.73     Missed  -242.2
 31 2021                                                
 Dec. 31 2020  -0.29       -0.29      -0.87     Missed  -200​
 Sep. 30 2020  -0.42       -0.42      -0.40     Beat    5.9
 Jun. 30 2020  -0.41       -0.41      -0.66     Missed  -59
 This summary was machine generated August 10 at 12:32 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on PLx Pharma Winddown

See all news